The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. (3rd July 2018)

• Record Type: Journal Article
• Authors: Pacini, Greta; Cavalli, Giulio; Tomelleri, Alessandro; De Luca, Giacomo; Pacini, Guido; Ferrarini, Marina; Doglioni, Claudio; Dagna, Lorenzo
• Is Part Of: Oncoimmunology. Volume 7:Number 7(2018)
• Publication Date: 2018-07-03
• Subjects: Erdheim-Chester disease -- fibrosis -- CCL-18; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1440929
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Erdheim-Chester disease (ECD) is a rare histiocytosis, characterized by xanthogranulomatous tissue infiltration by foamy histiocytes. Fibrosis, a histologic hallmark of ECD, is responsible for lesion growth and clinical manifestations. Unraveling molecular fibrotic pathway in ECD would allow the identification of new pharmacologic targets. In this study, we evaluated serum and tissue samples from a large cohort of ECD patients focusing on two major pro-fibrotic mediators, TGF-β1 and chemokine ligand 18 (CCL18). We found a marked increase in CCL18 but not TGF-β1 levels in serum and lesions of ECD patients ( p < 0.001 ), independently of treatment status and consistently over time. Using a linear mathematical model, we also found that elevated CCL18 serum levels correlate with both number and severity of disease localizations. These findings suggest the involvement of CCL18-induced fibrosis in ECD pathogenesis, providing a rationale for exploring CCL18 inhibition as a treatment for progressive fibrosis in ECD.